Clinical Trial

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-23.
Trial Details
NCT Number NCT07369024
Lead Sponsor Mohsen Saidinejad
Conditions Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Enrollment 120 participants
Start Date 2026-04-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-09